Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Molecular characterization — RAS/RAF status, microsatellite instability (MSI), and immune checkpoint expression — is essential for treatment selection. abinScience provides reagents targeting KRAS, BRAF, MMR proteins (MLH1/MSH2/MSH6/PMS2), CEA, EGFR, and PD-1/PD-L1 for CRC research and biomarker validation. RUO
Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.
Yes. We offer antibodies for all four MMR proteins — MLH1, MSH2, MSH6, and PMS2 — for IHC assessment of mismatch repair deficiency in CRC FFPE tissue. These are research use only.
We offer both polyclonal anti-KRAS antibodies that detect wild-type and common mutant forms, as well as recombinant KRAS proteins (wild-type and G12C/G12D/G12V) as assay controls.
Yes. Multiple anti-CEA/CEACAM5 clones available: 1A088, 1A089 (ELISA, IHC, WB), SAA1208 (ELISA, FC, IF, WB), BW250/183 (FC; FITC/APC/PE/PerCP conjugates). Recombinant CEA proteins also available.
Yes — HER2 amplification in CRC (~3%) is targetable with trastuzumab + pertuzumab. We offer anti-HER2 antibodies (IHC, WB) and biosimilar-grade reference proteins for comparability studies.
Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.
Human
ELISA, FCM, WB
Human
IgG1, kappa
SAA2012
Human
FCM
Human
IgG1, kappa
16D7
APC
Human
FCM
Human
IgG1, kappa
MN14
Human
FCM
Human
IgG1, kappa
RG7813
Human
FCM
Human
IgG1, kappa
4D5V8
Human
FCM
Human
IgG2, kappa
E7.6.3
Human
ELISA, FCM, WB
Human
IgG1, kappa
11F8
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-kappa/G1-lambda
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-kappa
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
scFv-Human IgG1, kappa
MEDI4276